CLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial

Stock News04-09

CLOVER BIO-B (02197) rose more than 7% again, with the stock up 5.21% at the time of writing to HK$3.03, with a turnover of HK$30.65 million. The increase follows the company's announcement that its self-developed proprietary respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), have completed patient recruitment in an Australian Phase II clinical trial. Preliminary clinical results are expected to be announced in the third quarter of 2026. Additionally, CLOVER BIO-B recently reached a settlement with Gavi, the Vaccine Alliance. Under the settlement terms, the company will make a one-time upfront payment of $7 million and is responsible for semi-annual deferred payments, along with contingent payments linked to future cash revenue. The total payment cap is set at a mid-range level of tens of millions of dollars, significantly lower than Gavi's initial claim of $224 million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1158381822?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 14:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158381822","market":"sg","top_or_hot":-1,"title":"CLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial","media":"Stock News","content":"<p>CLOVER BIO-B (02197) rose more than 7% again, with the stock up 5.21% at the time of writing to HK$3.03, with a turnover of HK$30.65 million. The increase follows the company's announcement that its self-developed proprietary respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), have completed patient recruitment in an Australian Phase II clinical trial. Preliminary clinical results are expected to be announced in the third quarter of 2026. Additionally, CLOVER BIO-B recently reached a settlement with Gavi, the Vaccine Alliance. Under the settlement terms, the company will make a one-time upfront payment of $7 million and is responsible for semi-annual deferred payments, along with contingent payments linked to future cash revenue. The total payment cap is set at a mid-range level of tens of millions of dollars, significantly lower than Gavi's initial claim of $224 million.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCLOVER BIO-B Shares Surge Over 7% Again on Progress in Respiratory Combo Vaccine Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-09 14:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOVER BIO-B (02197) rose more than 7% again, with the stock up 5.21% at the time of writing to HK$3.03, with a turnover of HK$30.65 million. The increase follows the company's announcement that its self-developed proprietary respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), have completed patient recruitment in an Australian Phase II clinical trial. Preliminary clinical results are expected to be announced in the third quarter of 2026. Additionally, CLOVER BIO-B recently reached a settlement with Gavi, the Vaccine Alliance. Under the settlement terms, the company will make a one-time upfront payment of $7 million and is responsible for semi-annual deferred payments, along with contingent payments linked to future cash revenue. The total payment cap is set at a mid-range level of tens of millions of dollars, significantly lower than Gavi's initial claim of $224 million.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VXUS","symbol_name":"国际股票ETF-Vanguard","start_time":0,"source_url":"","article_id":"1158381822","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158381822","pubTimestamp":1775717201,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOVER BIO-B (02197) rose more than 7% again, with the stock up 5.21% at the time of writing to HK$3.03, with a turnover of HK$30.65 million. The increase follows the company's announcement that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VXUS":"国际股票ETF-Vanguard","02197":"三叶草生物-B","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK1161":"生物科技"},"translate_title":"由于呼吸道组合疫苗试验取得进展，CLOVER BIO-B股价再次飙升超过7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1,"VXUS":1},"content_text":"CLOVER BIO-B (02197) rose more than 7% again, with the stock up 5.21% at the time of writing to HK$3.03, with a turnover of HK$30.65 million. The increase follows the company's announcement that its self-developed proprietary respiratory combination vaccine candidates, SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), have completed patient recruitment in an Australian Phase II clinical trial. Preliminary clinical results are expected to be announced in the third quarter of 2026. Additionally, CLOVER BIO-B recently reached a settlement with Gavi, the Vaccine Alliance. Under the settlement terms, the company will make a one-time upfront payment of $7 million and is responsible for semi-annual deferred payments, along with contingent payments linked to future cash revenue. The total payment cap is set at a mid-range level of tens of millions of dollars, significantly lower than Gavi's initial claim of $224 million.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1158381822","isCrawlerRequest":true}